Deborah Axelrod

Deborah Axelrod

Auto-generated profile, based on publicly available information

Deborah Axelrod

Department of Surgery, New York University School of Medicine, NYU Perlmutter Cancer Center, New York, USA

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2012 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SASylvia Adams
Sylvia Adams
LKLina Kozhaya
Lina Kozhaya
FMFrank Martiniuk
Frank Martiniuk
TMTze-Chiang Meng
Tze-Chiang Meng
LCLuis Chiriboga
Luis Chiriboga
SDSandra Demaria
Sandra Demaria
Purpose: Skin metastases of breast cancer remain a therapeutic challenge. Toll-like receptor 7 agonist imiquimod is an immune response modifier and can induce immune-mediated rejection of primary skin malignancies when topically applied. Here we tested the hypothesis that topical imiquimod stimulates local antitumor immunity and induces the regression of breast cancer skin metastases. Experimental Design: A prospective clinical trial was designed to evaluate the local tumor response rate of breast cancer skin metastases treated with topical imiquimod, applied 5 d/wk for 8 weeks. Safety and immunologic correlates were secondary objectives. Results: Ten patients were enrolled and completed the study. Imiquimod treatment was well tolerated, with only grade 1 to 2 transient local and systemic side effects consistent with imiquimod's immunomodulatory effects. Two patients achieved a partial response [20%; 95% confidence interval (CI), 3%–56%]. Responders showed histologic tumor regression with evidence of an immune-mediated response, showed by changes in the tumor lymphocytic infiltrate and locally produced cytokines. Conclusion: Topical imiquimod is a beneficial treatment modality for breast cancer metastatic to skin/chest wall and is well tolerated. Importantly, imiquimod can promote a proimmunogenic tumor microenvironment in breast cancer. Preclinical data generated by our group suggest superior results with a combination of imiquimod and ionizing radiation and we are currently testing in patients whether the combination can further improve antitumor immune and clinical responses. Clin Cancer Res; 18(24); 6748–57. ©2012 AACR.

Verified
Journal Article
Open access
PDF file
MFMei Fu
Mei Fu
DADeborah Axelrod
Deborah Axelrod
AGAmber A. Guth
Amber A. Guth
CCCharles M. Cleland
Charles M. Cleland
CRCaitlin E. Ryan
Caitlin E. Ryan
GMGail D'Eramo Melkus
Gail D'Eramo Melkus
Many breast cancer survivors have coexistent chronic diseases or comorbidities at the time of their cancer diagnosis. The purpose of the study was to evaluate the association of comorbidities on breast cancer survivors’ quality of life. A prospective design was used to recruit 140 women before cancer surgery, 134 women completed the study. Comorbidities were assessed using self-report and verified by medical record review and the Charlson Comorbidity Index (CCI) before and 12-month after cancer surgery. Quality of life was evaluated using Short-Form Health Survey (SF-36 v2). Descriptive statistics, chi-square tests, t-tests, Fisher’s exact test, and correlations were performed for data analysis. A total of 28 comorbidities were identified. Among the 134 patients, 73.8% had at least one of the comorbidities, 54.7% had 2–4, and only 7.4% had 5–8. Comorbidities did not change at 12 months after surgery. Numbers of comorbidities by patients’ self-report and weighted categorization of comorbidities by CCI had a similar negative correlation with overall quality of life scores as well as domains of general health, physical functioning, bodily pain, and vitality. Comorbidities, specifically hypertension, arthritis, and diabetes, were associated with poorer quality of life in multiple domains among breast cancer survivors. Future research should consider the combined influence of comorbidity and cancer on patients’ quality of life.

20 December 2008 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
JRJohn Rescigno
John Rescigno
JZJamie C. Zampell
Jamie C. Zampell
DADeborah Axelrod
Deborah Axelrod

6 November 2006 in Pain Practice
Verified
Journal Article
Closed access
PDF file
JKJung T. Kim
Jung T. Kim
MWMichael Wajda
Michael Wajda
GCGermaine Cuff
Germaine Cuff
DSDavid Serota
David Serota
MSMichael Schlame
Michael Schlame
ABAlex Y. Bekker
Alex Y. Bekker

6 February 2010 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MFMei Fu
Mei Fu
CCConstance M. Chen
Constance M. Chen
JHJudith Haber
Judith Haber
AGAmber A. Guth
Amber A. Guth
DADeborah Axelrod
Deborah Axelrod

1 April 2011 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
JJJinlong Jian
Jinlong Jian
QYQing Yang
Qing Yang
JDJisen Dai
Jisen Dai
JEJonathan Eckard
Jonathan Eckard
DADebrah Axelrod
Debrah Axelrod
XHXi Huang
Xi Huang